Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
SMC
Record ID 32018001090
English
Authors' objectives:
To assess clinical and cost effectiveness.
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/ravulizumab-ultomiris-full-smc2305/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/ravulizumab-ultomiris-full-smc2305/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Hemoglobinuria, Paroxysmal
- Hemolysis
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Atypical Hemolytic Uremic Syndrome
- Complement Inactivating Agents
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.